Home Featured Page 296

Featured

Latest

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation...

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Catching Up With the Psychedelic Entourage Effect: Part 5 – MindMed

The Psychedelic Entourage Effect: Part 6 – The State of the...

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

Ketamine-Assisted Couple Therapy Training by Enamory

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of Psychedelic Action

The Psychedelic Writers Guild’s Denver Mixer

The Mushroom Cure – Special Live Filming

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Mydecine Announces Exclusive Partnership and Increased Capabilities with Applied Pharmaceutical Innovation...

NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase...

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Catching Up With the Psychedelic Entourage Effect: Part 5 – MindMed

The Psychedelic Entourage Effect: Part 6 – The State of the...

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry...

Bright Minds Biosciences Inc. Announces Pricing of Public Marketed Offering of...

Researchers to Investigate Whether DMT Can Accelerate Recovery from Stroke

DMT Pricing Guide

EDITOR PICKS

Ketamine-Assisted Couple Therapy Training by Enamory

Quarterly Briefing: Q1 2026

Serotonin, Synapses, and Setting: Gitte Moos Knudsen on the Neurobiology of...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY